NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Merriman from Neutral to Buy. Company has likely reversed market share losses.
downgraded at Jesup & Lamont from Buy to Hold. Valuation call, as the stock is up 42% over the past month.
upgraded at Oppenheimer from Perform to Outperform. $20.50 price target. Company has strong operating and earnings momentum.
Charles River Laboratories
upgraded at Morgan Stanley from Underweight to Equal-weight. $44 price target. Expect positive data points around demand for pre-clinical toxicology studies.
upgraded at BofA/Merrill to Buy from Neutral on industrial production recovery, upbeat margin outlook, and compelling valuation. Price target surged to $90 from $58. 2010 EPS estimate raised to $4.17 , 2011 set at $6.
downgraded at BofA/Merrill to Neutral from Buy driven by price and margin declines, and valuation. 2010 EPS estimate lowered by 5 cents to $1.40. $36 price target.
downgraded at BofA/Merrill to Underperform from Buy on valuation. NFLX's 26% rise YTD is pricing in an overly optimistic scenario. $70 price target.
downgraded at Kaufman from Buy to Hold. Valuation call, based on a $69 price target.
downgraded at Susquehanna to Neutral. Valuation call, as the stock is up more than 30% since late December.
coverage was reinstated with a Buy rating at Goldman Sachs. $75 price target. Estimates also raised, as the bottling deal should be accretive to earnings.
upgraded at Goldman from Sell to Neutral. Estimates also boosted, given higher demand in the hydraulics market. $71 price target.
downgraded at Goldman from Buy to Neutral. Stock also cut from the Conviction List, as new investments will weigh on earnings. $26 price target.
upgraded at FBR from Market Perform to Outperform. $24 price target. Company is positioned well to benefit from improving industry fundamentals.
initiated at BofA/Merrill with a Neutral rating and $14 price target. Earnings growth is dependent on margin improvement.
initiated at Barclays with an Equal Weight rating and $13 price target. 2010 and 2011 EPs estimates set at $1.51 and $1.73, respectively.
reinstated at Credit Suisse with a Neutral rating and $23 price target. 2010 and 2011 EPS estimates set at $1.45 and $1.75, respectively.
STOCK COMMENTS / EPS CHANGES
target, estimate boosted at Barclays. APC price target increased by a dollar to $82 after the company raised volume growth forecasts at its analyst day. 2010 EPS estimate lifted to $1.30, 2011 introduced at $2.15. Overweight rating.
estimates, target increased at Goldman. AZO estimates were boosted through 2012. Company is realizing better gross margins. Neutral rating and new $169 price target.
numbers raised at Goldman. Shares of CAKE now seen reaching $28.50. Estimates also boosted, as the company has several areas to improve sales and margins. Buy rating.
estimates boosted at FBR through 2011. Company talked about continued fundamental improvement at its analyst day. Outperform rating and $18 price target.
estimates, target boosted at Goldman. Shares of CMI now seen reaching $68. Estimates also raised, because of higher components margins. Buy rating.
target, estimates raised at Credit Suisse. CYMI price target jumped to $45 from $40 as the company is a clear leader in EUV source lasers. Reiterate Outperform rating. 2010 EPS estimate raised to $2.75 from $2.63.
added to Conviction Buy List at Goldman. Company has attractive exposure to commercial trucks. $16 price target.
price target boosted at BofA/Merrill to $15 from $13 to reflect higher earnings and diminishing balance sheet concerns. 2010 and 2011 EPS estimates lifted to $1.12 and $1.22, respectively. Maintain Neutral rating.
numbers raised at Morgan Stanley. Shares of DTE now seen reaching $46.50. Estimates were also boosted, given improving fundamentals. Equal-weight rating.
estimate changed at Barclays. MA 2011 EPS estimates introduced at $16.50, maintain 2010 at $13.60. Reiterate Overweight rating and $272 price target.
estimates cut at UBS. MDR estimates were reduced through 2011. Company is seeing lower bookings and higher interest expense. Buy rating and $30 price target.
estimates upped at UBS through 2011. Company is seeing sales at the high end of expectations. Buyback should also help earnings. Buy rating and $49 price target.
estimates lowered at FBR through 2011. Company is guiding toward lower margins. Underperform rating and $21 price target.
estimates changed at Credit Suisse. SPLS 2011 EPS lowered to $1.35, 2012 introduced at $1.68. Maintain Outperform rating and $29 price target.
estimates boosted at UBS through 2011. Company is better positioned than its peers to play offense. Neutral rating and new $23 price target.
This article was written by a staff member of TheStreet.com.